A message from Porter & Company Editor’s Note: This might be the most important investing broadcast of the year. Legendary forecaster Porter Stansberry and Jeff Brown expose one of the most important and consequential financial stories in America today. They say it’s a coordinated, government-backed mobilization that’s funneling trillions of dollars into a tiny handful of companies. For more details, click here. Or read on below to hear from Porter himself… You won’t want to accept this. You’ll reject it. Call me crazy for suggesting it. I don’t care. I’m used to it. That’s what they called me when I predicted the fall of Fannie Mae and Freddie Mac, the bankruptcy of General Motors, the loss of America’s triple-A credit rating… the list goes on and on. But I don’t let my emotions blind me to reality. No matter how difficult the truth… no matter how uncomfortable the fact… I follow my research to its logical conclusion. You should too. But I know most of you won’t – or can’t. However, if you have any money in the stock market, savings in the bank – and especially if you are responsible for your family’s wealth – you really need to hear me out. What I’ve discovered took months of investigation… and years of watching this moment build in the background of everyday life. A powerful force — one almost no one fully understands — is on the verge of tearing through American life and wealth with brutal efficiency. It won’t be fair. It won’t be gradual. And it won’t spare the unprepared. Hundreds of millions will feel the impact. Some could be devastated. A few others will come out far richer. Which side you end up on may come down to one thing: how fast you act. My job is simple: to make sure you land on the right side of what’s coming. This force, described by Elon Musk as “the most likely cause of World War 3, demands a response. And it’s getting one. It’s the reason Trump has been raising trillions of dollars from the Middle East… The reason he forced Zelensky to hand over rights to half of Ukraine’s enormous mineral deposits… It’s the reason Apple is spending $500 billion to bring their factories back to U.S. soil. It’s even behind the President’s strange obsession with Greenland. The threat of this force looms so large that Trump has privately declared it a national emergency… mobilizing public and private capital on a scale we haven’t seen since the Second World War. In fact, strange as this may sound, what’s unfolding eerily resembles America’s transition to a total war state, 85 years ago. Back then, key industrial assets were “drafted” to support the war effort. Boeing, GM, Ford, and Caterpillar were called on to produce tanks, fighter planes, and radar. Today, the President has recruited the likes of Apple’s Tim Cook, Amazon’s Jeff Bezos, Mark Zuckerberg, and OpenAI’s Sam Altman… to tap their vast resources for his own, undeclared national emergency. Why has he called upon the world’s largest companies and wealthiest men? As you’ll see, trillions of dollars are rapidly being directed into a concentrated set of companies closely connected to this national emergency. In this special broadcast, Jeff Brown and I will reveal what this national emergency is and how Trump and his team are reordering the entire economy to prepare for it. More importantly, we’ll name the two companies most likely to profit. This new emergency could determine who retires rich — and who gets wiped out, as it forces an epic rotation of capital from one side of the market to the other. You still have time to prepare – but not much. In a matter of days, an expected announcement from Trump could send capital flooding into the companies we share in the broadcast. That’s why we’re urging you to watch today. 
Good investing, Porter Stansberry
P.S. This is already underway. Money is rapidly moving. And we believe several popular stocks could be decimated by it. Don’t wait to be engulfed by it – prepare now. Go here.
Today's Featured Content Ozempic Boom: Hims & Eli Lilly Lead Healthcare BetsWritten by Gabriel Osorio-Mazilli. Published 8/21/2025. Edited Article  
Key Points - The race inside the weight loss industry is ramping up, leaving investors with three names to choose from when it comes to playing this theme.
- From diversification to aggressive expansion, investors can tailor-make their healthcare portfolios.
- Institutions are behind this momentum, and it seems there is more upside ahead.
That theme is the Ozempic wave. Ozempic—a GLP-1 weight-loss therapy—has reached millions of American households over the past few years, and its momentum shows no signs of slowing despite recent regulatory scrutiny and legal challenges. New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it's the first sign that "Trump's Great Gain" has officially begun.
Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he's laying out the full gameplan in a new presentation. See Altucher's Trump crypto prediction here Data now clearly demonstrate that consumers appreciate the product and achieve meaningful results. Enter companies like Hims & Hers Health Inc. (NYSE: HIMS) and Eli Lilly and Co. (NYSE: LLY), both of which are directly exposed to the Ozempic/weight-loss market. But before weighing the risk-reward profiles of these names, investors may want to consider a more diversified play: the Health Care Select Sector SPDR Fund (NYSEARCA: XLV). Why Diversification Matters As with any emerging drug or therapy, the road to broad adoption can be bumpy. Spreading bets across multiple companies can help manage volatility, offering greater stability in exchange for potentially more modest gains. XLV currently trades at a roughly 26% discount to the broader S&P 500, suggesting this sector could be a value zone for investors reluctant to concentrate their capital in a single stock. Looking ahead, we may see rotation back into healthcare—away from hypergrowth tech and toward defensive, income-generating sectors—boosting this ETF in the process. An Exciting Ride: Hims & Hers Often viewed solely as a weight-loss play, Hims & Hers has built a broader consumer health platform, with dermatology, sexual wellness and mental health offerings as well as GLP-1 therapies. That diversification sets it apart from traditional drugmakers. Its subscription-based model generates recurring revenue and provides downside protection, unlike bulk drug wholesale channels. Hims & Hers boasts a formidable 76.2% gross profit margin—rare territory even for software companies—and analysts at firms such as Nomura Holdings have taken notice. Nomura built an $8 million stake in mid-August 2025, highlighting confidence in the company's fundamentals and growth runway. This vote of confidence underpins the case for further upside over the coming quarters—or even years. Stability in Scale: Eli Lilly While Hims & Hers carries a $10 billion market cap, Eli Lilly's $663 billion valuation gives it vast resources to scale up production and distribution of Ozempic and follow-on therapies. Wall Street has awarded Lilly a consensus Moderate Buy rating and a $950.20 price target. Trading at just 72% of its 52-week high, the stock implies roughly 36% upside. Eli Lilly's size and experience translate to lower volatility—a beta of 0.44 versus 2.10 for Hims & Hers—offering a more conservative way to participate in the GLP-1 revolution.
| 
0 Response to "Trump’s national nightmare is here"
Post a Comment